1/29/2015 0 Comments
Celgene reported revenue of $2.086B in Q4, in-line with consensus. EPS of $1.01 was also in-line. Celgene did lower 2015 product sale guidance by $100M citing a currency headwind. Margin guidance was good. I view this stock as a buy on weakness.
Michael Grove, CFA